Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus.
Several lines of evidence suggest a major role of calcitonin gene-related peptide (CGRP) in the pathogenesis of migraine and other primary headaches. Inhibition of CGRP receptors by olcegepant and telcagepant has been successfully used to treat acute migraine and to reduce the activity of spinal trigeminal neurons involved in meningeal nociception in rodents. The site of CGRP receptor inhibition is unclear, however. In adult Wistar rats anaesthetized with isofluorane systemic intravenous infusion (0.9 mg/kg) or unilateral facial injection (1 mM in 100 microl) of capsaicin was used to induce activity in the trigeminal nociceptive system. Animals were pre-treated either by saline or olcegepant. In comparison with vehicle infusion or the non-injected side of the face, capsaicin significantly increased the expression of the activation markers Fos in the spinal trigeminal nucleus and phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion. Pre-treatment with olcegepant (900 microg/kg) inhibited the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%. In contrast, the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion was not changed by olcegepant pre-treatment. CGRP receptor inhibition, which has been shown to decrease spinal trigeminal activity, is likely to occur in the central nervous system rather than in the periphery including the trigeminal ganglion. This may be important for future therapeutic interventions with CGRP receptor antagonists in migraine.
Sixt
Marie-Luise
ML
Institute of Physiology and Pathophysiology, University of Erlangen-Nürnberg, Universitätstrasse 17, 91054 Erlangen, Germany.
Messlinger
Karl
K
Fischer
Michael J M
MJ
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D002211:Capsaicin / Q000494:pharmacology; D004151:Dipeptides / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy / Q000378:metabolism; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010146:Pain / Q000139:chemically induced / Q000378:metabolism; D010879:Piperazines; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D011799:Quinazolines / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014279:Trigeminal Nucleus, Spinal / Q000166:cytology / Q000187:drug effects*
D015415:Biomarkers; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004151:Dipeptides; D010879:Piperazines; D016760:Proto-Oncogene Proteins c-fos; D011799:Quinazolines; D048049:Extracellular Signal-Regulated MAP Kinases; D015740:Calcitonin Gene-Related Peptide; D002211:Capsaicin; C406305:olcegepant